Allakos Drops After Regeneron Eosinophilic Esophagitis Study Hits Endpoints

Shares of Allakos are lower after Regeneron Pharmaceuticals announced yesterday that Part A of a Phase 3 trial evaluating Dupixent in patients 12 years and older with eosinophilic esophagitis met both of its co-primary endpoints.